Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

Regulated Information - Denominator

Atlas Special Opportunities, LLC has converted 22 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment¹ that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Leuven, BELGIUM, Boston, MA, US – May 31, 2023 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of (i) 45,289,855 new ordinary shares on May 30, 2023, for a total amount of EUR 150,000, as the result of the conversion of 6 convertible bonds, and (ii) 125,418,060 new ordinary shares on May 31, 2023, for a total amount of EUR 400,000, as the result of the conversion of 16 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 1,022,343,629 outstanding ordinary shares carrying voting rights (compared to 851,635,714 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

Share capital (EUR)	79,906,161
Total number of securities with voting rights (all ordinary shares)	1,022,343,629
Total number of ordinary shares (= denominator)	1,022,343,629
Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
591,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 591,500 securities carrying voting rights (all ordinary shares); 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares); 972,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 972,250 securities carrying voting rights (all ordinary shares); 532,500 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 532,500 securities carrying voting rights (all ordinary shares); 614,249 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 614,249 securities carrying voting rights (all ordinary shares); 184 convertible bonds issued on March 14, 2023, April 20, 2023, and May 22, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023; and 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).

END